Alzheimer's disease

Cassava Sciences (NASDAQ:SAVA) stock is falling Monday after the company shared an update on its Phase 3 trial for a treatment for Alzheimer's disease that has been widely followed by the market. Martin Shkreli, a well-know figure in the pharmaceutical space, predicted the stock’s crash...

A recent study has found that dronabinol, a synthetic version of THC (the primary psychoactive component in cannabis), effectively reduces agitation in Alzheimer's patients. Presented at the International Psychogeriatric Association conference in Buenos Aires, Argentina, the study reveals that...

Barbara Corcoran, renowned real estate mogul and star of “Shark Tank,” has opened up about her personal encounter with Alzheimer’s disease, following the loss of her mother to the condition. What Happened: Corcoran’s mother, Florence, succumbed to Alzheimer’s 12 years...

In Tuesday’s pre-market trading, ANEW Medical, Inc. (NASDAQ:WENA) saw its shares surge nearly 80% following an announcement about the advancement of its patented Klotho gene therapy program for neurodegenerative disorders. What Happened: ANEW, a biopharmaceutical company that specializes in...

In a significant development in the battle against Alzheimer’s disease, the U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company’s (NYSE:LLY) Alzheimer’s treatment, “Kisunla.” What Happened: As per the official press release on Tuesday, Kisunla (...

InMed Pharmaceuticals is making strides in Alzheimer’s research with its development of a cannabinoid-based compound that aims to protect and rejuvenate brain neurons. During Benzinga’s virtual event on Thursday, InMed president and CEO Eric A. Adams shared detailed insights into the...

Biogen Inc (NASDAQ:BIIB) is pulling the plug on its Aduhelm Alzheimer’s disease drug more than two years after the drug came into the limelight after receiving controversial FDA approval. Biogen said on Wednesday it would discontinue developing and commercializing Aduhelm (aducanumab-avwa)...

Cannabidiol (CBD), a non-psychoactive compound found in the cannabis plant, has emerged as a potential therapeutic agent for Alzheimer's Disease. While research is still in the early stages, several studies have shown that CBD may help prevent and alleviate some of the disease’s symptoms...

Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins (white matter) from the brain have sparked a renewed interest in developing vaccines to combat this memory-robbing disease.  Clinical trials for at least seven Alzheimer's disease...

Cannformatics, an early-stage biotechnology company, has unveiled a groundbreaking advancement in the field of medical cannabis treatment for Autism Spectrum Disorder (ASD). Their recent publication in Nature's Scientific Reports highlights the use of Cannabis-Responsive (C-Res) biomarkers and...

IGC Pharma, Inc. (IGC), a leading cannabinoid-based formulation developer, has expanded its Phase 2 clinical trial for IGC-AD1, a natural THC-based investigational drug for Alzheimer's disease, to the University of Puerto Rico network. IGC is dedicated to developing advanced cannabinoid-based...

The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval. Alzheimer’s disease is a brain disease that leads to cognitive decline, impacting more than six...

FloraWorks, a cannabinoid therapeutics company specializing in rare and novel cannabinoids, has successfully completed a $2.25 million Series-A financing round. Leading this significant investment was life sciences venture capital firm, Bonaventure Equity LLC. Other participants in the round...

MorphoSys AG's (NASDAQ: MOR) partner Roche Holdings AG (OTC: RHHBY) announced results from the GRADUATE I and II studies evaluating gantenerumab in mild cognitive impairment (MCI) due to Alzheimer's and mild Alzheimer's dementia. The studies did not meet their...

SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system announced positive interim results from its Phase IIa trial of SCI-110 in patients with Alzheimer’s Disease (...